Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine
- PMID: 3327449
Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine
Abstract
Immunofluorescent studies in human prostatic carcinoma cells (DU 145) and cultured squirrel fish epithelial cells (a non-cancer cell) revealed that estramustine, a conjugate of estradiol and nor-nitrogen mustard, possessed microtubule disassembly properties. Sixty microM estramustine produced disassembly at both the proximal and distal ends of microtubules, producing short pieces of less than 2 microM which were "wavy" and oriented in a random manner. With increased time of drug exposure these short microtubules disappeared, to be accompanied by a gradual disassembly of a small population of longer microtubules (greater than 7-8 microM). In dividing DU 145 cells it was possible to show a different degree of sensitivity of specific microtubule-containing cellular structures. In mitotic figures the asters were most sensitive and disappeared completely following exposure to estramustine. These were followed by the "pole-to-pole" and "chromosomal" fibers. In cytokinesis, the intercellular fibers between daughter cells were comparatively resistant to the drug. Estramustine did not induce disassembly of the vimentin filaments in non-dividing or dividing cells but did cause their collapse around the nucleus or the mitotic apparatus. These data suggest that specific microtubules have differing sensitivity to estramustine.
Similar articles
-
The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells.Eur J Cell Biol. 1991 Apr;54(2):268-76. Eur J Cell Biol. 1991. PMID: 1879438
-
Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.Cancer Res. 1988 Apr 1;48(7):1842-9. Cancer Res. 1988. PMID: 3349462
-
Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.Cancer Res. 1992 Aug 15;52(16):4433-40. Cancer Res. 1992. PMID: 1353706
-
Mechanism based chemotherapy for prostate cancer.Cancer Surv. 1991;11:239-54. Cancer Surv. 1991. PMID: 1841754 Review.
-
Intracellular effects of estramustine (Estracyt/Emcyt).Prog Clin Biol Res. 1989;303:169-75. Prog Clin Biol Res. 1989. PMID: 2674983 Review. No abstract available.
Cited by
-
Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.J Cell Biol. 1988 Dec;107(6 Pt 2):2647-56. doi: 10.1083/jcb.107.6.2647. J Cell Biol. 1988. PMID: 3060470 Free PMC article.
-
The antineoplastic agent estramustine and the derivative estramustine-phosphate inhibit secretion of interleukin-3 in leukemic cells. Possible roles of MAPs.Mol Cell Biochem. 1992 Nov 18;117(2):165-73. doi: 10.1007/BF00230756. Mol Cell Biochem. 1992. PMID: 1488050
-
Concurrent chemoradiation for high-risk prostate cancer.World J Clin Oncol. 2015 Aug 10;6(4):35-42. doi: 10.5306/wjco.v6.i4.35. World J Clin Oncol. 2015. PMID: 26266099 Free PMC article. Review.